New immunotherapy epcoritamab shows promise for Hard-to-Treat lymphoma in japanese patients
NCT ID NCT04542824
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study tests a drug called epcoritamab in Japanese patients whose B-cell lymphoma has returned or not responded to treatment. The drug works by helping the immune system find and attack cancer cells. The trial has two parts: first, finding a safe dose, and then checking how well it works alone or with standard chemotherapy. About 78 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Aichi, Japan
-
Cancer Institute Hospital of JFCR
Tokyo, Japan
-
Fukushima Medical University Hospital
Fukushima, Japan
-
Kagoshima University Hospital
Kagoshima, Japan
-
Kindai University Hospital
Osaka, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Matsuyama Red Cross Hospital
Ehime, Japan
-
NHO Nagoya Medical Center
Aichi, Japan
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Hospital East
Chiba, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
-
Osaka University Hospital
Osaka, Japan
-
Tohoku University Hoaspital
Sendai, Miyagi, 980-8577, Japan
-
Tokyo Medical University Hospital
Tokyo, Japan
-
Yamagata University Hospital
Yamagata, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epcoritamab (a type of immunotherapy that helps the immune system attack cancer cells)
What this could lead to
If successful, this could provide a new treatment option for Japanese patients with B-cell lymphoma that has come back or not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to everyone. Side effects from immunotherapy can be serious, including immune system overreactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.